Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

ects to enroll approximately 160 patients across 40 centers worldwide and to report top-line results in the second half of 2012.
  • Kuvan Outcomes Study: PKU-016, a randomized, placebo-controlled, 13-week Kuvan outcomes study is ongoing.  Endpoints include clinically validated measures of neuropsychiatric symptoms and if successful, may enable a label amendment.  The company expects to report top-line results in the second half of 2012.
  • Hand-Held Blood Phe Monitor: Several programs are underway to expand and protect the market and to improve the ability of healthcare providers and patients to better manage PKU.  Regulatory clearance and commercial availability of the handheld blood Phe monitor are expected between the first quarter of 2013 and the third quarter of 2013.
  • Firdapse: BioMarin initiated a Phase III trial for LEMS in the U.S. in the second quarter of 2011.  

  • Mid-Stage Clinical Programs

  • PEG-PAL for PKU: Top-line results for the Phase II study, including a formulation study and the ongoing daily dosing study are expected in the third or fourth quarter of 2011.  The company expects to initiate a Phase III trial in the first or second quarter of 2012.

  • Early-Stage Clinical Programs

  • BMN-701 for Pompe Disease: BioMarin initiated a Phase I/II trial in Pompe patients in the first quarter of 2011.  The trial is an open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN-701 administered as an intravenous infusion every two weeks at doses of 5 mg/kg, 10 mg/kg and 20 mg/kg.  The company expects to enroll up to 30 patients between the ages of 13 and 65 years old with late-onset Pompe disease for a treatment period of 24 weeks.  The primary objective of the study is to establish the maximum tolerated dose of every other week administration of BMN-701 and to trea
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    2. BioMarin Announces FDA Approval for Kuvan
    3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    8. BioMarin to Present at the Oppenheimer Healthcare Conference
    9. BioMarin Announces Third Quarter 2009 Financial Results
    10. BioMarin to Acquire LEAD Therapeutics
    11. BioMarin to Present at the Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... 1, 2014  CVS Health is thanking its 26,000 ... in changing the way health care is delivered to ... Company,s retail pharmacies, mail service pharmacies and specialty pharmacies ... company name to CVS Health to reflect our broader ... innovations needed to shape the future of health," said ...
    (Date:9/30/2014)... , Sept. 30, 2014  Wrightington, ... and Allscripts (NASDAQ: MDRX ) are delighted ... solution as WWL,s new health information system. The system ... will completely transform the way WWL delivers healthcare in ... of a demonstrated record of on-time and on-budget system ...
    (Date:9/30/2014)... 30, 2014 STUDY OBJECTIVES The ... to provide an overview of the current and ... drugs/therapeutics. The key objective is to present a ... as an important tool in the treatment of ... future strategies within the protein therapeutics market, which ...
    Breaking Medicine Technology:CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
    ... Mo., Sept. 10 K-V Pharmaceutical Company (NYSE:  KVa/KVb) ... U.S. Food and Drug Administration ("FDA") of the successful ... approval to return its first product to market.  Under ... Company,s quality systems, processes and facilities are expected to ...
    ... CITY, Calif., Sept. 9 Avinger, Inc., a ... innovative devices to combat peripheral artery disease, announces ... CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat ... prospective, multi-center, non-randomized study intended to evaluate the ...
    Cached Medicine Technology:K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8First Patient Enrolled in 'CONNECT' Clinical Trial 2
    (Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
    (Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
    (Date:10/1/2014)... to keep their "eyes on the prize" may be ... staying focused on a specific target ahead can make ... walk there faster, psychology researchers have found. Their study, ... the environment naturally, offers a new strategy to improve ... in exercise if physical activity seems daunting, which can ...
    (Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining how ... family members. , Life insurance plans provide important financial ... should always carry a life insurance policy as their ... the family. , Clients can choose from several ... coverage or from a permanent policy. No medical exam ...
    (Date:10/1/2014)... First Warning Systems, a pioneer in early ... the body, announced the company is changing its name ... breadth of upcoming product releases. The initial focus will ... “Our initial focus will be an ‘Internet of Everthing,’ ... cellular changes over time,” said Rob Royea, president and ...
    Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4
    ... drugs to fix what healthy living would cure, researcher says, ... eating right, exercising and keeping your weight down are well-known, ... , In fact, over the past two decades exercise rates ... in the meantime obesity rates have soared, a new study ...
    ... TORONTO, Ont., May 28, 2009 When Chicago Blackhawk,s ... game four of the Western Conference Final after sustaining ... surrounding his swift return. According to a new study ... questions were raised by 25% of minor league hockey ...
    ... leaders for vision, determination and drive to address today,s ... , a part of Experian and a leader ... that its president, Daniel Johnson, has been named as ... the Year(R) Award in Minnesota and the Dakotas."I am ...
    ... the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish ... been made by the responsible Grants Committee of the ... centres will initially be funded for four years with ... this, the DFG will also provide 20 percent overhead ...
    ... launches campaign for stricter regulatory approval requirements and continuity of product ... ... 2009 -- A recent report released by Wolters Kluwer Health predicts ... drug prescriptions will be filled with generic drugs. This march ...
    ... HEIGHTS, Ohio, May 27 Allscripts announced today ... Allscripts Professional(R) Electronic Health Record ... multi-specialty practices across suburban Cleveland, Ohio. (Logo: ... hospital and health center with its own physician ...
    Cached Medicine News:Health News:Americans Score Low on Healthy Lifestyle 2Health News:Americans Score Low on Healthy Lifestyle 3Health News:Minor league hockey players unable to identify concussion symptoms, study says 2Health News:Minor league hockey players unable to identify concussion symptoms, study says 3Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 3Health News:DFG establishes nine new collaborative research centers 2Health News:DFG establishes nine new collaborative research centers 3Health News:DFG establishes nine new collaborative research centers 4Health News:DFG establishes nine new collaborative research centers 5Health News:DFG establishes nine new collaborative research centers 6Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 2Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 3Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 4Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 5Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 2Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 3Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 4Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 5
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: